Explore a selection of our essential drug information below, or:
Identification
- Summary
Cefoxitin is a semi-synthetic, broad-spectrum antibiotic for parenteral administration used for the treatment of serious bacterial infections, such as urinary tract infection, blood infection, bone and joint infection, and lower respiratory tract infection.
- Generic Name
- Cefoxitin
- DrugBank Accession Number
- DB01331
- Background
Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Cefoxitin (DB01331)
- Weight
- Average: 427.452
Monoisotopic: 427.050791293 - Chemical Formula
- C16H17N3O7S2
- Synonyms
- (6R,7S)-4-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(thiophen-2-enyl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- Cefoxitin
- Cefoxitina
- Cefoxitine
- Cefoxitinum
- Ceftoxitin
- Cephoxitin
- CFX
- Rephoxitin
- External IDs
- J01DC01
Pharmacology
- Indication
For the treatment of serious infections caused by susceptible strains microorganisms.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Animal bite ••• ••••• Treatment of Bacterial infections •••••••••••• Treatment of Bacterial urinary tract infections •••••••••••• Treatment of Endometritis •••••••••••• Treatment of Gynecological infection •••••••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Cefoxitin is a cephamycin antibiotic often grouped with the second-generation cephalosporins. It is active against a broad range of gram-negative bacteria including anaerobes. The methoxy group in the 7a position provides cefoxitin with a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases, of gram-negative bacteria.
- Mechanism of action
The bactericidal action of cefoxitin results from inhibition of cell wall synthesis.
Target Actions Organism AD-alanyl-D-alanine carboxypeptidase DacC inhibitorEscherichia coli (strain K12) AD-alanyl-D-alanine carboxypeptidase DacA inhibitorEscherichia coli (strain K12) AD-alanyl-D-alanine endopeptidase inhibitorEscherichia coli (strain K12) AD-alanyl-D-alanine carboxypeptidase DacB inhibitorEscherichia coli (strain K12) APenicillin-binding protein 1A inhibitorEscherichia coli (strain K12) APenicillin-binding protein 1B inhibitorEscherichia coli (strain K12) APeptidoglycan synthase FtsI inhibitorEscherichia coli (strain K12) APenicillin-binding protein 3 inhibitorStreptococcus pneumoniae APenicillin-binding protein 1b inhibitorStreptococcus pneumoniae (strain ATCC BAA-255 / R6) APenicillin-binding protein 2a inhibitorStreptococcus pneumoniae (strain ATCC BAA-255 / R6) APenicillin-binding protein 1A inhibitorStreptococcus pneumoniae (strain ATCC BAA-255 / R6) APenicillin-binding protein 2B inhibitorStreptococcus pneumoniae (strain ATCC BAA-255 / R6) - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
Minimal (approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period).
- Route of elimination
Approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period, resulting in high urinary concentrations. Cefoxitin passes into pleural and joint fluids and is detectable in antibacterial concentrations in bile.
- Half-life
The half-life after an intravenous dose is 41 to 59 minutes.
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The acute intravenous LD50 in the adult female mouse and rabbit was about 8.0 g/kg and greater than 1.0 g/kg, respectively. The acute intraperitoneal LD50 in the adult rat was greater than 10.0 g/kg.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Cefoxitin may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefoxitin. Aceclofenac The risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Aceclofenac. Acemetacin The risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding can be increased when Cefoxitin is combined with Acenocoumarol. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Cefoxitin sodium Q68050H03T 33564-30-6 GNWUOVJNSFPWDD-XMZRARIVSA-M - International/Other Brands
- Cefoctin (Teva) / Cenomicin (Daiichi-Seiyaku) / Mefoxitin (Merck)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Cefoxitin and Dextrose Injection, solution 2 g/50mL Intravenous B. Braun Medical Inc. 2006-03-10 Not applicable US 
Cefoxitin and Dextrose Injection, solution 1 g/50mL Intravenous B. Braun Medical Inc. 2006-03-10 Not applicable US Cefoxitin for Injection Powder, for solution 1 g / vial Intramuscular; Intravenous TEVA Canada Limited 1995-12-31 Not applicable Canada 
Cefoxitin for Injection Powder, for solution 10 g / vial Intramuscular; Intravenous TEVA Canada Limited 2000-01-01 Not applicable Canada Cefoxitin for Injection Powder, for solution 2 g / vial Intramuscular; Intravenous TEVA Canada Limited 1995-12-31 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Cefoxitin Powder, for solution 1 g/1 Intravenous Fresenius Kabi USA, LLC 2011-07-06 Not applicable US Cefoxitin Injection, powder, for solution 2 g/10mL Intravenous WG Critical Care, LLC 2013-10-01 2015-02-20 US Cefoxitin Injection, powder, for solution 10 g/1 Intravenous Apotex Corporation 2006-02-13 2019-05-31 US Cefoxitin Injection, powder, for solution 1 g/1 Intravenous Hikma Farmaceutica 2010-03-12 2010-03-12 US Cefoxitin Injection, powder, for solution 10 g/1 Intravenous Sagent Pharmaceuticals 2010-08-12 Not applicable US
Categories
- ATC Codes
- J01DC01 — Cefoxitin
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as cephalosporin 3'-carbamates. These are cephalosporins that are substituted at the 3'-position by a carbamate group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Lactams
- Sub Class
- Beta lactams
- Direct Parent
- Cephalosporin 3'-carbamates
- Alternative Parents
- Cephamycins / N-acyl-alpha amino acids and derivatives / 1,3-thiazines / Thiophenes / Tertiary carboxylic acid amides / Carbamate esters / Heteroaromatic compounds / Secondary carboxylic acid amides / Azetidines / Organic carbonic acids and derivatives show 10 more
- Substituents
- Alpha-amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Azetidine / Carbamic acid ester / Carbonic acid derivative / Carbonyl group / Carboxamide group / Carboxylic acid / Carboxylic acid derivative show 19 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- cephalosporin, semisynthetic derivative, cephamycin (CHEBI:209807)
- Affected organisms
- Enteric bacteria and other eubacteria
Chemical Identifiers
- UNII
- 6OEV9DX57Y
- CAS number
- 35607-66-0
- InChI Key
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
- InChI
- InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1
- IUPAC Name
- (6R,7S)-3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[2-(thiophen-2-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- SMILES
- [H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O
References
- Synthesis Reference
Pandurang Deshpande, Bhausaheb Khadangale, "Process for the preparation of cefoxitin." U.S. Patent US20060252928, issued November 09, 2006.
US20060252928- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015426
- KEGG Drug
- D02345
- KEGG Compound
- C06887
- PubChem Compound
- 441199
- PubChem Substance
- 46505845
- ChemSpider
- 389981
- BindingDB
- 50335563
- 2189
- ChEBI
- 209807
- ChEMBL
- CHEMBL996
- ZINC
- ZINC000003830449
- Therapeutic Targets Database
- DAP000452
- PharmGKB
- PA448856
- PDBe Ligand
- CFX
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Cefoxitin
- PDB Entries
- 4kow
- FDA label
- Download (76.5 KB)
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Prevention Antibiotics Prophylaxis / Bariatric Surgery Candidates / Obesity 1 somestatus stop reason just information to hide Not Available Terminated Treatment Acute Pyelonephritis Without Severity Symptoms Due to ESBL-producing E.Coli 1 somestatus stop reason just information to hide 4 Completed Other Antibiotic pre-surgical prophylaxis 1 somestatus stop reason just information to hide 4 Terminated Treatment Urinary Tract Infection 1 somestatus stop reason just information to hide 3 Active Not Recruiting Treatment Pancreatic Cancer / Pancreatic Diseases 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Apotex Inc.
- APP Pharmaceuticals
- B. Braun Melsungen AG
- Baxter International Inc.
- Bioniche Pharma
- GC Hanford Manufacturing Co.
- GlaxoSmithKline Inc.
- Hikma Pharmaceuticals
- Merck & Co.
- Orchid Healthcare
- Sagent Pharmaceuticals
- West-Ward Pharmaceuticals
- Dosage Forms
Form Route Strength Injection, powder, for solution Injection, powder, for solution Intramuscular Injection, powder, for solution Intravenous 1 g/10mL Injection, powder, for solution Intravenous 10 g/100mL Injection, powder, for solution Intravenous 100 g/1 Injection, powder, for solution Intravenous 2 g/10mL Powder, for solution Intravenous 1 g/1 Powder, for solution Intravenous 2 g/1 Powder, for solution Intramuscular; Intravenous 1 g / vial Powder, for solution Intramuscular; Intravenous 10 g / vial Powder, for solution Intramuscular; Intravenous 2 g / vial Powder Intravenous Injection Intramuscular 500 MG Injection Intravenous 500 MG Injection, powder, for solution Intramuscular; Parenteral 1 G/2ML Injection, powder, for solution Intravenous 1 g/1 Injection, powder, for solution Intravenous 10 g/1 Injection, powder, for solution Intravenous 2 g/1 Injection, powder, for solution Intravenous; Parenteral 1 G/10ML Injection, powder, for solution Intravenous; Parenteral 2 G/20ML Injection, solution Intravenous 1 g/50mL Injection, solution Intravenous 2 g/50mL Powder, for solution Intravenous 1 g / vial Powder, for solution Intravenous 2 g / vial Powder, for solution Intravenous 10 g / vial Powder Intravenous 500 mg/1vial - Prices
Unit description Cost Unit Cefoxitin 10 gm vial 112.25USD vial Cefoxitin 2 gm vial 26.28USD vial Cefoxitin 2 gm piggyback bag 22.56USD each Cefoxitin 1 gm vial 13.12USD vial Cefoxitin 1 gm piggyback bag 12.3USD each DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 165-167 Christiansen, B.G. and Firestone, R.A.; US. Patent 3,775,410; November 27, 1973; assigned Hazen, G.C.; U.S. Patent 3,780,033; December 18, 1973; assigned to Merck & Company, Inc. logP -0.02 SANGSTER (1993) - Predicted Properties
Property Value Source Water Solubility 0.195 mg/mL ALOGPS logP 0.22 ALOGPS logP 0.29 Chemaxon logS -3.3 ALOGPS pKa (Strongest Acidic) 3.39 Chemaxon pKa (Strongest Basic) -3.8 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 148.26 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 98.76 m3·mol-1 Chemaxon Polarizability 39.47 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.7203 Blood Brain Barrier - 0.9952 Caco-2 permeable - 0.7898 P-glycoprotein substrate Substrate 0.8198 P-glycoprotein inhibitor I Non-inhibitor 0.8831 P-glycoprotein inhibitor II Non-inhibitor 0.9715 Renal organic cation transporter Non-inhibitor 0.9085 CYP450 2C9 substrate Non-substrate 0.8655 CYP450 2D6 substrate Non-substrate 0.8241 CYP450 3A4 substrate Substrate 0.5389 CYP450 1A2 substrate Non-inhibitor 0.786 CYP450 2C9 inhibitor Non-inhibitor 0.8214 CYP450 2D6 inhibitor Non-inhibitor 0.8642 CYP450 2C19 inhibitor Non-inhibitor 0.7954 CYP450 3A4 inhibitor Non-inhibitor 0.9312 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8753 Ames test Non AMES toxic 0.6912 Carcinogenicity Non-carcinogens 0.9329 Biodegradation Not ready biodegradable 0.979 Rat acute toxicity 1.6623 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9951 hERG inhibition (predictor II) Non-inhibitor 0.8518
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0005-9324000000-05cb1df27c44fb10d1f0 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-014i-0009200000-6482009cde6e3d8e3ace Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0udi-0159000000-0437b91cd9b6026a45c9 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-016s-2059400000-38b513f0d0afafd7ded4 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-05mx-5179000000-37b13176f20989d23e18 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0002-5779100000-fe98f705db46132fe035 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-002p-9861000000-a185b44d446d00848a56 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 206.7217374 predictedDarkChem Lite v0.1.0 [M-H]- 206.7761374 predictedDarkChem Lite v0.1.0 [M-H]- 188.00989 predictedDeepCCS 1.0 (2019) [M+H]+ 207.7868374 predictedDarkChem Lite v0.1.0 [M+H]+ 206.8537374 predictedDarkChem Lite v0.1.0 [M+H]+ 190.3679 predictedDeepCCS 1.0 (2019) [M+Na]+ 207.3497374 predictedDarkChem Lite v0.1.0 [M+Na]+ 207.6639374 predictedDarkChem Lite v0.1.0 [M+Na]+ 196.78415 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type d-ala-d-ala carboxypeptidase activity
- Specific Function
- Removes C-terminal D-alanyl residues from sugar-peptide cell wall precursors.
- Gene Name
- dacC
- Uniprot ID
- P08506
- Uniprot Name
- D-alanyl-D-alanine carboxypeptidase DacC
- Molecular Weight
- 43608.595 Da
References
- Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [Article]
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type d-ala-d-ala carboxypeptidase activity
- Specific Function
- Removes C-terminal D-alanyl residues from sugar-peptide cell wall precursors.
- Gene Name
- dacA
- Uniprot ID
- P0AEB2
- Uniprot Name
- D-alanyl-D-alanine carboxypeptidase DacA
- Molecular Weight
- 44443.62 Da
References
- Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [Article]
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type d-ala-d-ala carboxypeptidase activity
- Specific Function
- Cell wall formation. May play a specialized role in remodeling the cell wall. Specifically hydrolyzes the DD-diaminopimelate-alanine bonds in high-molecular-mass murein sacculi.
- Gene Name
- pbpG
- Uniprot ID
- P0AFI5
- Uniprot Name
- D-alanyl-D-alanine endopeptidase
- Molecular Weight
- 33887.085 Da
References
- Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [Article]
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type d-ala-d-ala carboxypeptidase activity
- Specific Function
- Not involved in transpeptidation but exclusively catalyzes a DD-carboxypeptidase and DD-endopeptidase reaction.
- Gene Name
- dacB
- Uniprot ID
- P24228
- Uniprot Name
- D-alanyl-D-alanine carboxypeptidase DacB
- Molecular Weight
- 51797.85 Da
References
- Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [Article]
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type d-ala-d-ala carboxypeptidase activity
- Specific Function
- Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan str...
- Gene Name
- mrcA
- Uniprot ID
- P02918
- Uniprot Name
- Penicillin-binding protein 1A
- Molecular Weight
- 93635.545 Da
References
- Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [Article]
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type d-ala-d-ala carboxypeptidase activity
- Specific Function
- Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan str...
- Gene Name
- mrcB
- Uniprot ID
- P02919
- Uniprot Name
- Penicillin-binding protein 1B
- Molecular Weight
- 94291.875 Da
References
- Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [Article]
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Peptidoglycan glycosyltransferase activity
- Specific Function
- Essential cell division protein that is required for the synthesis of peptidoglycan at the division septum (PubMed:1103132, PubMed:9614966). Catalyzes the synthesis of cross-linked peptidoglycan fr...
- Gene Name
- ftsI
- Uniprot ID
- P0AD68
- Uniprot Name
- Peptidoglycan synthase FtsI
- Molecular Weight
- 63876.925 Da
References
- Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [Article]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type d-ala-d-ala carboxypeptidase activity
- Specific Function
- Not Available
- Gene Name
- pbp3
- Uniprot ID
- Q75Y35
- Uniprot Name
- Penicillin-binding protein 3
- Molecular Weight
- 45209.84 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Transferase activity, transferring acyl groups
- Specific Function
- Not Available
- Gene Name
- pbp1b
- Uniprot ID
- Q7CRA4
- Uniprot Name
- Penicillin-binding protein 1b
- Molecular Weight
- 89479.92 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Transferase activity, transferring acyl groups
- Specific Function
- Not Available
- Gene Name
- pbp2a
- Uniprot ID
- Q8DNB6
- Uniprot Name
- Penicillin-binding protein 2a
- Molecular Weight
- 80797.94 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Penicillin binding
- Specific Function
- Cell wall formation.
- Gene Name
- pbpA
- Uniprot ID
- Q8DR59
- Uniprot Name
- Penicillin-binding protein 1A
- Molecular Weight
- 79700.9 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Not Available
- Specific Function
- Penicillin binding
- Gene Name
- penA
- Uniprot ID
- P0A3M6
- Uniprot Name
- Penicillin-binding protein 2B
- Molecular Weight
- 73872.305 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
Enzymes
- Kind
- Protein
- Organism
- Bacillus licheniformis
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Beta-lactamase activity
- Specific Function
- Not Available
- Gene Name
- penP
- Uniprot ID
- P00808
- Uniprot Name
- Beta-lactamase
- Molecular Weight
- 33995.36 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Song W, Lee KM, Kim HS, Kim JS, Kim J, Jeong SH, Roh KH: Clonal spread of both oxyimino-cephalosporin- and cefoxitin-resistant Klebsiella pneumoniae isolates co-producing SHV-2a and DHA-1 beta-lactamase at a burns intensive care unit. Int J Antimicrob Agents. 2006 Dec;28(6):520-4. Epub 2006 Nov 13. [Article]
- d'Azevedo PA, Goncalves AL, Musskopf MI, Ramos CG, Dias CA: Laboratory tests in the detection of extended spectrum beta-lactamase production: National Committee for Clinical Laboratory Standards (NCCLS) screening test, the E-test, the double disk confirmatory test, and cefoxitin susceptibility testing. Braz J Infect Dis. 2004 Oct;8(5):372-7. Epub 2005 Mar 17. [Article]
- Ke YY, Lin TH: A theoretical study on the activation of Ser70 in the acylation mechanism of cephalosporin antibiotics. Biophys Chem. 2005 Apr 22;114(2-3):103-13. Epub 2004 Nov 30. [Article]
Drug created at June 13, 2005 13:24 / Updated at September 15, 2024 01:12